Inactivation of Cancer Mutations Utilizing CRISPR/Cas9.

Gebler C1, Lohoff T1, Paszkowski-Rogacz M2, Mircetic J2, Chakraborty D2, Camgoz A2, Hamann MV2, Theis M2, Thiede C2, Buchholz F2.

Author information

Abstract

Although whole-genome sequencing has uncovered a large number of mutations that drive tumorigenesis, functional ratification for most mutations remains sparse. Here, we present an approach to test functional relevance of tumor mutations employing CRISPR/Cas9. Combining comprehensive sgRNA design and an efficient reporter assay to nominate efficient and selective sgRNAs, we establish a pipeline to dissect roles of cancer mutations with potential applicability to personalized medicine and future therapeutic use.